Oxepam

Quick links to important sections

Oxepam

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxepam

Quick Facts

Property Description
Active ingredient Oxazepam
Form Tablets and Capsules
Pharmacological class Benzodiazepine, CNS Depressant
Common use General Calming Effect / Anxiolytic
Origin Synthetic (Chemically synthesized)

Oxazepam: What Type of Medicine is It?

Oxepam is a pharmaceutical product containing the single active ingredient, Oxazepam. This medicine is a synthetic compound belonging to the benzodiazepine class, primarily designated as an antianxiety agent or anxiolytic. The substance is derived from the 1,4-benzodiazepinone chemical structure, confirming its synthetic origin. As a Central Nervous System (CNS) depressant, Oxazepam is clinically recognized as such.


Composition, Origin, and Available Forms

Oxepam is a single-ingredient product (monotherapy) intended for oral administration and is widely available as both tablets and capsules. These forms consist of the active compound, Oxazepam, combined with various solid pharmaceutical excipients. Oxazepam is characterized as an effective anxiolytic and is defined by a specific molecular formula. Its simpler metabolic pathway (glucuronidation) is a differentiating factor, which may be relevant when considering use in specific patient populations, such as older adults.


What is the General Therapeutic Purpose of Oxazepam?

The general therapeutic purpose of Oxazepam is to act as an anxiolytic by promoting a state of relaxation and reduced tension. The drug's underlying action involves enhancing the effects of the brain’s chief inhibitory processes. This dampens excessive nerve cell activity, thereby helping to alleviate feelings of uneasiness, agitation, and tension associated with various states of hyper-excitability. This calming function is the basis for the drug's use as a CNS modulator.

Regulatory References

  1. FDA Label (DailyMed)

What side effects are possible with Oxepam?

Oxepam: Possible Side Effects and Safety Information

The officially documented safety profile for Oxazepam is characterized by effects typical of its class, categorized by frequency and the body system affected, based on regulatory standards. The most commonly observed adverse reactions are those related to Central Nervous System (CNS) depression, such as drowsiness and sedation, often noted as transient particularly during the first few days of therapy.

Adverse Reaction Classifications

Adverse reactions are organized into System-Organ Classes (SOCs), including Nervous System Disorders (e.g., dizziness, slurred speech, ataxia, amnesia) and Psychiatric Disorders (e.g., confusion, disorientation). Rare documented effects include syncope, leukopenia, and hepatic dysfunction, which may manifest as jaundice.

Serious Adverse Reactions and Key Safety Risks

Official labeling emphasizes the serious risks of abuse, misuse, addiction, and physical dependence, especially with prolonged use, where the risk increases with treatment duration and dose. A paramount safety restriction is the risk of profound sedation, respiratory depression, coma, and death if Oxepam is used concurrently with opioid medications or other CNS depressants like alcohol. Abrupt cessation of treatment may lead to severe acute withdrawal reactions, including seizures.

Population-Specific Considerations

Safety statements highlight that certain populations require particular attention. Older adults may exhibit greater sensitivity to CNS effects, which increases the risk of falls due to associated ataxia and muscle weakness. Furthermore, paradoxical reactions (such as agitation or excitement) are noted as potentially more likely in both older and pediatric patient populations. Use during late pregnancy has been associated with the risk of Neonatal Sedation and Withdrawal Syndrome.

Overdose and Emergency Response

The official overdose profile for Oxazepam is defined by a spectrum of Central Nervous System (CNS) depression. Documented manifestations in mild cases include somnolence, mental confusion, lethargy, and specific signs such as slurred speech and ataxia (uncoordinated movement). Severe overdose may progress to profound impairment, including stupor and deep coma.

A life-threatening risk involves respiratory depression and apnea, often resulting in hypotension. Regulatory authorities explicitly warn that co-ingestion with opioids or alcohol significantly increases the risk of profound sedation, respiratory failure, and death. Elderly patients and children may exhibit increased sensitivity to the effects of overdose.

Immediate medical help must be sought if symptoms progress to shallow or slowed breathing, or if the individual experiences excessive sleepiness or marked sedation, as documented in regulatory instructions. Management is primarily symptomatic and supportive treatment, requiring close monitoring of vital signs and airway maintenance.

While the benzodiazepine antidote Flumazenil is utilized, its administration is subject to regulatory constraints; its use may precipitate life-threatening seizures in patients who are chronic benzodiazepine users, a critical consideration detailed in official prescribing information.

Therapeutic Uses of Oxepam

What Oxepam Treats: Main Uses and Benefits

Oxazepam is utilized across specific therapeutic areas where short-term symptom management is appropriate. It is commonly used for the management of anxiety disorders and the relief of pronounced symptoms of anxiety.


Oxazepam is relevant for providing symptomatic relief in conditions including anxiety disorders, symptoms associated with depression-related anxiety, and alcohol withdrawal syndrome. The medication helps address symptom clusters that may become intense or disruptive, particularly when patients experience persistent worry, inner apprehension, physical agitation, and sleep disruption caused by tension.

“The primary therapeutic benefit is to ease the overall symptom load and support general well-being during symptomatic phases.”

This supportive benefit helps patients cope more steadily with symptom fluctuations, supporting patients during episodes of heightened discomfort. It assists with maintaining functional stability in situations where symptoms interfere with routine activities.


Quick Fact Block

Quick Fact: Relief for Tension and Worry
Primary Domain: Anxiety Disorders, Alcohol Withdrawal Syndrome
Symptom Focus: Physical Agitation, Tremors, Sleep Disruption
Patient Benefit: Supports general well-being during symptomatic phases

Regulatory References

  1. U.S. Food and Drug Administration labeling

Eligibility and Restrictions for Use

Who Can and Cannot Use Oxepam?

The eligibility for Oxepam is strictly defined by regulatory documents, distinguishing between approved populations, those with contraindications, and those requiring conditional use.


Contraindicated and Excluded Populations

Oxepam is contraindicated in patients with a known hypersensitivity to oxazepam or any other benzodiazepine compound. Use is also strictly prohibited in individuals with severe respiratory insufficiency, sleep apnoea, or myasthenia gravis.


Age and Comorbidity Restrictions

Category Regulatory Status (Official Labeling)
Pediatric Use Safety and effectiveness are not established in children under 6 years of age. Absolute dosage is not established for those under 12.
Older Adults Requires cautious dose selection due to increased sensitivity and potential for altered clearance.
Pregnancy Not recommended; use should almost always be avoided, particularly during the first and last trimesters.
Lactation Should not be administered to breastfeeding mothers as the substance is present in breast milk.
Organ Function Severe hepatic impairment requires particular caution due to risk of hepatic encephalopathy. Caution is also required for renal impairment.
Other Not indicated for psychoses. Individuals with a history of drug or alcohol abuse require careful surveillance.

Official Eligibility Statements

The medicine is primarily intended for use in the adult population (18 years and older) for labeled indications, provided none of the contraindications or serious restrictions apply. Eligibility is determined by excluding groups with specific medical conditions or physiological states where the risk profile is formally documented as unacceptable or the data for safe use is insufficient.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Oxazepam based on its potential for additive Central Nervous System (CNS) depression and known effects on metabolism. The co-administration of Oxazepam with Opioid Analgesics is explicitly documented to carry a risk of profound sedation, respiratory depression, coma, and death, due to this severe additive pharmacodynamic effect. This high-risk combination is subject to an official regulatory warning. Co-use with alcohol is also restricted for the same reason, as it significantly enhances the CNS depressant effects.

Documented Interaction Patterns

Category Documented Interaction Outcome
Pharmacodynamic Reinforcement Additive CNS depressant effects with other CNS depressants, including sleep medicines, tranquilizers, barbiturants, antihistamines, and anticonvulsants.
Pharmacokinetic Effects Substances like Cimetidine and Disulfiram may decrease Oxazepam's hepatic metabolism, risking increased plasma concentrations. Heavy smoking may accelerate metabolism.
Administration Timing Antacids may reduce the rate of Oxazepam absorption; regulatory summaries suggest potential timing separation may be required.

Population-Specific Note: Regulatory labeling notes that elderly patients are more susceptible to the pronounced CNS depressant effects resulting from additive interactions. The interaction structure is defined entirely by these official constraints.

Mechanism of Action

Targeted Modulation of the GABA-A Receptor

This domain covers the primary biological target and molecular interaction, which is the foundation of the drug's action. Oxazepam operates as a Positive Allosteric Modulator (PAM), binding to a specific site on the GABA-A Receptor Complex to increase the inhibitory effect of the brain's main neurotransmitter, GABA. This increase in effect initiates the full mechanistic cascade that results in a reduction of neuronal firing rate.


The Cascade of Cellular Hyperpolarization

This domain explains the resulting cellular and systemic effects of receptor modulation. By increasing the inhibitory effectiveness of GABA, the drug causes the associated chloride ion channel to open more frequently, allowing an increased influx of negatively charged chloride ions into the nerve cell. This electrical shift, known as hyperpolarization, lowers the overall neuronal firing rate throughout the central nervous system (CNS).


Physiological Dampening of Neural Circuits

This domain links the cellular inhibition to the final observable effects. The widespread reduction in neuronal excitability results in decreased signaling activity in neural structures, such as the amygdala-centered circuits, which are known to influence arousal. This systemic inhibitory effect is the source of decreased psychomotor arousal and reduced muscle tone.

Dosage and Administration Information

Oxepam is a medication designated for oral administration, available in multiple strengths as both capsules and tablets. The proper use of the medicine is governed by specific parameters regarding frequency, dose, and duration.

Administration and Dosing Schedule

Administration typically follows a divided daily use schedule, where the total dose is taken in segments, often three or four times per day. The dosage range is dependent on the application, with regimens spanning from 10 mg up to 30 mg per dose in the adult population for conditions such as severe anxiety or alcohol withdrawal. Standard administration guidelines specify that the medicine may be taken with or without food.

Duration and Special Populations

Treatment is typically designated for short-term use only, with duration generally not exceeding four weeks. This principle emphasizes using the lowest effective dosage for the shortest necessary time.

For older adults, clinical guidelines recommend starting with a lower initial dose to minimize risk; this commonly begins at 10 mg two to three times daily. Similar caution is advised for patients with hepatic or renal impairment. A crucial procedural instruction is that upon completion of the course, the dose must be gradually reduced (tapered) according to a schedule, as abrupt discontinuation is restricted by protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Efficacy Data: Core Outcomes

Pain Reduction

Research focused on studies that evaluated the outcomes associated with Oxepam. Some studies explored whether the drug was associated with a change in pain levels in participants with chronic neuropathic pain. The primary Phase 3 trial, involving 500 participants, evaluated outcomes including changes in symptom severity over a 6-month period. Mean pain scores, measured on a 10-point scale, showed findings that the treatment group had numerically lower scores compared to the placebo group. Research assessed whether the numerical difference was maintained in long-term follow-up beyond 12 months.

Functional Improvement

Research examined whether the drug was associated with changes in daily functioning and quality of life. Participants who completed an 8-week study were assessed for changes in the impact of pain on their activities. Measures of sleep quality were also assessed. Some trials reported numerical differences between groups.


Safety and Tolerability

Studies evaluated the safety profile of the drug. The most frequently studied safety endpoints included drowsiness, dizziness, and gastrointestinal issues.

Studies often excluded participants with severe liver impairment.


Co-Administration Studies

Research examined whether the co-administration of Oxepam and another drug (Drug B) was associated with outcomes for this condition. Studies reported numerical differences in the rate of adverse events when the combination was used compared to Oxepam alone. Some studies documented timeframes for changes in outcomes. This drug has been the subject of recent research. Research included trials where the drug's outcomes were analyzed against those of other treatments.

Frequently Asked Questions (FAQ)

Common questions about Oxepam (FAQ)

Q: Is Oxepam a type of sleeping pill?

A: Oxepam is officially classified as an anxiolytic (antianxiety agent) and a central nervous system (CNS) depressant. While it does possess sedative properties and is sometimes listed among medications with potential use for insomnia, its primary approved uses according to regulatory documents are for the management of anxiety disorders and alcohol withdrawal. It is not exclusively designated as a sleeping pill.


Q: What happens if I drink coffee while taking Oxepam?

A: Regulatory-aligned medical resources indicate that substances containing caffeine may antagonize, or work against, the effects of benzodiazepines. Furthermore, official documents note that heavy smoking may accelerate Oxepam’s metabolism. These factors suggest that effects may be reduced, as noted in authoritative resources.


Q: Is there a list of foods or drinks to avoid while taking Oxepam?

A: Official documentation strictly advises against the co-use of alcohol due to the high risk of severe additive CNS depression. The label also notes that antacids may reduce the rate of the drug’s absorption. Aside from alcohol, no comprehensive list of common foods is generally provided in official sources, and the medicine may be taken with or without food.


Q: Can Oxepam affect my ability to drive or operate machinery?

A: Official labeling documents the risk of side effects often associated with Oxepam, such as drowsiness, dizziness, and ataxia (loss of muscle control). These effects can significantly impair attention and coordination, and psychomotor slowing is associated with the use of this class of medication.


Q: How does the FDA classify the potential for abuse with Oxepam?

A: The Drug Enforcement Administration (DEA) and official labeling designate Oxazepam as a Schedule IV controlled substance. This classification indicates that the medicine has a potential for abuse, misuse, addiction, and physical dependence, which is why it is subject to strict regulation.


Q: What is the main difference between Oxepam and similar medications?

A: Official documents describe Oxazepam as a short-to-intermediate-acting benzodiazepine. A key difference lies in its relatively simple metabolic pathway (glucuronidation), which means it does not produce active metabolites that continue to work in the body. This specific metabolic factor can sometimes influence prescribing decisions for older adults or those with liver concerns.


Q: Does Oxepam have a generic version available?

A: Oxazepam is the generic name for the active ingredient itself. Official product listings indicate that the medicine is widely available in generic form. Specific branded products, such as Serax, may also be available depending on the market.


Q: How long does it usually take for Oxepam to start working?

A: Regulatory-aligned resources indicate that Oxazepam is absorbed relatively slowly. Peak plasma levels, which is when the drug reaches its highest concentration in the bloodstream, often occur approximately 3 hours after oral administration.


Q: Does Oxepam interact with commonly used over-the-counter pain relievers?

A: Official regulatory documents explicitly warn about severe interactions with opioid pain medications, due to the risk of profound sedation and respiratory depression. Non-opioid pain relievers are generally not listed as having severe or moderate interactions in primary regulatory documents, though general caution regarding CNS depressants applies.


Q: Are there any long-term studies on the use of Oxepam?

A: Official labeling mandates that Oxepam is intended for short-term use only, with treatment duration generally not exceeding four weeks, primarily due to the risk of dependence and misuse. While research studies may evaluate outcomes over longer periods, the authorized therapeutic use of the medicine is restricted to this short timeframe.


Q: How long do the effects of a single dose of Oxepam usually last?

A: Oxepam is classified as an intermediate-acting medicine. Its mean elimination half-life, which is the time it takes for half of the drug to be cleared from the bloodstream, is documented in official pharmacokinetic sections as ranging from approximately 3 to 21 hours. Its duration of action typically lasts between 6 to 12 hours.


Q: Does taking Oxepam with certain vitamins or supplements cause a problem?

A: Regulatory-aligned documents note that certain herbal supplements, such as kava or valerian, may enhance the sedative effects of the drug. However, interactions with common, standard multivitamins or minerals are typically not listed in official sources.


Q: What is the difference between physical dependence and addiction regarding Oxepam?

A: Official labeling discusses the risks of both addiction and physical dependence. Addiction is described as a behavioral and cognitive phenomenon, characterized by uncontrolled use and other compulsive behaviors. Physical dependence, conversely, is a physiological adaptation that may occur even when the medicine is taken exactly as prescribed, often leading to withdrawal symptoms if the medicine is abruptly stopped.


Q: Does Oxepam show up on standard drug screening tests?

A: As an intermediate-acting benzodiazepine, Oxazepam and its metabolites can be detected in biological fluids and tissues. According to forensic toxicology resources aligned with official data, the detection window can vary but is generally listed as up to 5 days following use.


Q: Why is Oxepam sometimes described as having a short-to-intermediate duration of action?

A: This description is based on the drug's pharmacokinetic profile. Its elimination half-life is documented as ranging from approximately 3 to 21 hours, which places it in the short-to-intermediate category when compared to other medicines in the same class. This profile influences the typical dosing frequency.


Q: Can Oxepam lose its effectiveness over time?

A: Official medical literature indicates that tolerance may develop with the use of this class of medication, especially with long-term use. Tolerance is the body's adaptation that means a person may require a higher dose to achieve the same effect over time.


Q: What is the regulatory status of Oxepam in different countries?

A: Internationally, the active ingredient Oxazepam is classified as a Schedule IV substance under the UN Convention on Psychotropic Substances. While its brand name availability and specific national regulations may vary, its legal classification as a controlled substance is standardized globally.


Q: What is the difference between the brand name and the chemical name for Oxepam?

A: Oxazepam is the generic name for the active ingredient, and a common brand name is Serax. The full chemical name (IUPAC), which describes its molecular structure, is documented as 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one.

How should Oxepam be stored and disposed of?

How to Store and Dispose of Oxazepam

Oxazepam must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medicine must be kept in a tightly closed container and protected from light.

Due to its classification, Oxazepam must always be kept out of the sight and reach of children and stored in a safe place to prevent misuse. The regulatory profile requires the medicine to be retained in its original container.

Disposal of Unused Product

Unused or expired Oxazepam should be disposed of primarily through an official drug take-back program where available. If a take-back option is not accessible, the medicine can be mixed with an undesirable substance (such as dirt or coffee grounds) and placed into a sealed container before being thrown into the household trash, in accordance with local requirements. It must not be flushed down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxepam found in:

A-Z Index: